|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9768
|
|
pubmed:dateCreated |
2011-3-7
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:ArnsWolfgangW,
pubmed-author:BeckerThomasT,
pubmed-author:BuddeKlemensK,
pubmed-author:EisenbergerUteU,
pubmed-author:FischerWolfgangW,
pubmed-author:GschaidmeierHaraldH,
pubmed-author:KramerStefanS,
pubmed-author:LidaYY,
pubmed-author:PietruckFrankF,
pubmed-author:ReinkePetraP,
pubmed-author:SommererClaudiaC
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
377
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
837-47
|
|
pubmed:dateRevised |
2011-6-14
|
|
pubmed:meshHeading |
pubmed-meshheading:21334736-Administration, Oral,
pubmed-meshheading:21334736-Adolescent,
pubmed-meshheading:21334736-Adult,
pubmed-meshheading:21334736-Aged,
pubmed-meshheading:21334736-Calcineurin,
pubmed-meshheading:21334736-Cyclosporine,
pubmed-meshheading:21334736-Female,
pubmed-meshheading:21334736-Glomerular Filtration Rate,
pubmed-meshheading:21334736-Graft Rejection,
pubmed-meshheading:21334736-Humans,
pubmed-meshheading:21334736-Immunosuppressive Agents,
pubmed-meshheading:21334736-Kidney Failure, Chronic,
pubmed-meshheading:21334736-Kidney Transplantation,
pubmed-meshheading:21334736-Male,
pubmed-meshheading:21334736-Middle Aged,
pubmed-meshheading:21334736-Mycophenolic Acid,
pubmed-meshheading:21334736-Sirolimus,
pubmed-meshheading:21334736-TOR Serine-Threonine Kinases,
pubmed-meshheading:21334736-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
|
|
pubmed:affiliation |
Department of Nephrology, Charité University, Berlin, Germany. klemens.budde@charite.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
